- Direct clinical evidence for cinnamon specifically in IBS is very limited — there are no large, well-designed randomised controlled trials (RCTs) to date.
- Cinnamon has demonstrated anti-spasmodic and antimicrobial properties in lab and small-scale studies, which is biologically plausible for IBS, but plausibility is not proof.
- High doses of cassia cinnamon contain coumarin, a compound that can be toxic to the liver — a real safety concern if you're experimenting with therapeutic amounts.
- People with IBS should not replace evidence-based management strategies with cinnamon based on current data.
What the evidence shows
The honest answer is: not much, and not yet. If you search for clinical trials testing cinnamon against IBS specifically, the cupboard is nearly bare. A small Iranian RCT by Vejdani et al. (2006) tested a herbal combination including cinnamon alongside other botanicals (peppermint and caraway) and found some symptomatic benefit — but this cannot be attributed to cinnamon alone, and the sample size was too small to draw firm conclusions. No large, well-controlled trial has isolated cinnamon and measured it head-to-head against placebo in an IBS population.
What we do have is indirect, mechanistic evidence. Cinnamon contains bioactive compounds — chiefly cinnamaldehyde — that have shown antispasmodic effects on gut smooth muscle in animal and in-vitro work (Hagenlocher et al., 2013). There is also modest evidence that cinnamon extract can reduce gut motility and act against certain bacteria that may overgrow in some IBS subtypes (Friedman, 2017). Again, these are lab findings, not outcomes in people sitting in a gastroenterologist's waiting room.
For context, compare this with the evidence base for peppermint oil in IBS, which has multiple RCTs and a Cochrane-level meta-analysis supporting its short-term use (Alammar et al., 2019). Cinnamon is not in that league. If you are looking for a well-evidenced, natural antispasmodic for IBS, peppermint oil in enteric-coated form has meaningfully stronger support.
Some researchers have studied cinnamon for blood sugar regulation (Khan et al., 2003; Allen et al., 2013), and blood sugar swings can affect gut motility and IBS-like symptoms in some people — but this is a very indirect pathway and not evidence that cinnamon treats IBS.
How it works (mechanism)
The leading active compound in cinnamon is cinnamaldehyde, which gives the spice its characteristic smell and flavour. In laboratory models, cinnamaldehyde has been shown to relax intestinal smooth muscle, potentially reducing cramping and spasm (Hagenlocher et al., 2013). Cinnamon also contains polyphenols with mild anti-inflammatory properties, and both Ceylon and cassia cinnamon have demonstrated some antimicrobial activity against bacteria like Escherichia coli and Helicobacter pylori (Friedman, 2017).
The theory, then, is that these combined effects — muscle relaxation, reduced inflammation, and selective antimicrobial action — could dampen the bloating, cramping, and irregular motility characteristic of IBS. The theory is biologically coherent. The gap is the clinical evidence that the theory plays out in actual IBS patients at achievable dietary doses.
Dose & timing if you try it
Because the evidence is thin, there is no validated therapeutic dose for IBS. What the safety literature does allow us to say:
- Ceylon cinnamon ("true cinnamon," Cinnamomum verum) is considerably lower in coumarin than cassia cinnamon and is the safer choice if you are using more than a culinary pinch regularly.
- The European Food Safety Authority (EFSA) set a tolerable daily intake for coumarin at 0.1 mg per kg of body weight. Cassia cinnamon can contain 1–12 mg coumarin per gram; Ceylon cinnamon contains roughly 0.017 mg per gram — orders of magnitude less.
- Culinary use (½–1 teaspoon of Ceylon cinnamon per day in food or drinks) is generally considered safe for most adults and is consistent with amounts used in some of the small studies cited above.
- Timing: no evidence guides specific timing relative to meals for IBS. Most culinary use is with food, which is sensible.
- If you try a standardised supplement, look for Ceylon cinnamon extract and follow the manufacturer's maximum dose. Treat any dose above culinary range as a supplement requiring caution, not a guaranteed benefit.
Keep a symptom diary. If you notice no improvement after four to six weeks of consistent use, the evidence does not support continuing.
Who should skip
- People with liver disease or elevated liver enzymes — coumarin in cassia cinnamon has documented hepatotoxic potential at higher doses (Haber et al., 2021).
- Pregnant individuals — high-dose cinnamon has historically been used to stimulate uterine contractions; supplemental doses during pregnancy are not established as safe and should be avoided.
- Anyone taking warfarin or other anticoagulants — cinnamon has mild anti-platelet properties and coumarin is structurally related to warfarin; the interaction risk is real even if not fully quantified.
- People with diabetes on medication — cinnamon can modestly lower blood glucose (Allen et al., 2013); combined with hypoglycaemic drugs, this risks low blood sugar episodes.
- Children under 12 — insufficient safety data for supplemental doses.
- Anyone with known cinnamon or cassia allergy — contact dermatitis and oral allergy reactions are reported (Nettis et al., 2002).
Bottom line
Cinnamon is not a well-evidenced choice for IBS symptom management. The mechanistic rationale is plausible, and it is a harmless culinary spice at normal cooking amounts — but no one should be swapping their low-FODMAP diet, fibre adjustment, or clinician-prescribed treatment for a cinnamon supplement based on the evidence available in 2024. If you enjoy cinnamon in food and want to continue using it, that is reasonable. If you are hoping it will meaningfully move the needle on your IBS bloating or pain, the current research does not support that expectation.
Work with a gastroenterologist or a registered dietitian familiar with IBS. Interventions with real clinical evidence — including low-FODMAP dietary approaches (Gibson & Shepherd, 2010) and enteric-coated peppermint oil (Alammar et al., 2019) — are better starting points.
References
- Alammar, N., et al. (2019). The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complementary and Alternative Medicine, 19(1), 21.
- Allen, R.W., et al. (2013). Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Annals of Family Medicine, 11(5), 452–459.
- Friedman, M. (2017). Chemistry, antimicrobial mechanisms, and antibiotic activities of cinnamaldehyde against pathogenic bacteria in animal feeds and human foods. Journal of Agricultural and Food Chemistry, 65(48), 10406–10423.
- Gibson, P.R., & Shepherd, S.J. (2010). Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. Journal of Gastroenterology and Hepatology, 25(2), 252–258.
- Haber, S.L., et al. (2021). Cinnamon: potentially beneficial but not without risk. The Consultant Pharmacist, 36(2), 73–81.
- Hagenlocher, Y., et al. (2013). Cinnamon extract inhibits degranulation and de novo synthesis of inflammatory mediators in mast cells. Allergy, 68(4), 490–497.
- Khan, A., et al. (2003). Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care, 26(12), 3215–3218.
- Nettis, E., et al. (2002). IgE-mediated allergy to cinnamon. Allergy, 57(10), 957–958.
- Vejdani, R., et al. (2006). The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome. Digestive Diseases and Sciences, 51(8), 1501–1507.
- Limited high-quality evidence: No large RCT has specifically isolated cinnamon as a monotherapy for IBS to date.